Sign inJoin waitlistJoin the waitlist

Elizabeth Krakow

Associate Professor, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

McMaster Children's Hospital
2006–2007
Internal Medicine
Duke University Hospital
2003–2006
Doctor of Medicine
1999–2003

Research

Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease
Journal of Clinical Oncology · 2022 · 96 citations
Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation · 2018 · 80 citations
HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group
JAMA Oncology · 2018 · 43 citations

Stephanie Lee
12 papers
Mary Flowers
11 papers
Paul Carpenter
9 papers
Rachel Salit
9 papers
Laura Connelly-Smith
8 papers
Phuong Vo
5 papers
MB
Merav Bar
4 papers
AY
Albert Yeh
3 papers
Ann Dahlberg
3 papers
Brenda Sandmaier
3 papers
Cecilia Yeung
3 papers
Corinne Summers
3 papers

Clinical trials

DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Principal investigator · Suspended · Phase 1
Fred Hutchinson Cancer Center
2024–2028
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Principal investigator · Withdrawn · Phase 1
Fred Hutchinson Cancer Center
2020–2021
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Principal investigator · Recruiting · Phase 1
Fred Hutchinson Cancer Center
2018–2028
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Site PI · Recruiting · Phase 2
Sawa Ito, MD
2024–2029